Navigation Links
Signal protein shows promise for blocking tumor promoters in skin cells

A protein with the ironic name "Srcasm" can counteract the effects of tumor-promoting molecules in skin cells, according to new research by investigators at the University of Pennsylvania School of Medicine. Using animal models, the researchers discovered that Srcasm acts like a brake in epithelial cells, preventing uncontrolled cell growth caused by a family of proteins called Src kinases. This finding, published online in the Journal of Biological Chemistry, suggests a target for future gene therapy to treat skin, head, neck, colon, and breast cancers.

Investigators have known for decades that Src kinase proteins can promote tumor formation. Src kinase activity is elevated in most skin cancers and in common carcinomas, including those of the breast and colon. At the same time, levels of the signaling molecule Srcasm are typically low in tumor cells, notes senior author John Seykora, MD, PhD, Assistant Professor of Dermatology. The current findings show that Srcasm can reduce the amount of Src kinases in cells; they have also shown that increased activity of these kinases is associated with cancerous skin lesions.

Src kinase proteins act like messengers, sending signals that control cellular growth. Found just inside the cell membrane, they conduct signals from cell surface receptors to the proteins that promote growth. Src kinases can be activated during cell division or through mutation. If these proteins are too active, they promote rapid cell growth that can spin out of control. In skin cells, Src kinases and Srcasm are involved in signaling pathways that control cell growth and differentiation.

See Saw Action
The researchers decided to test whether Srcasm could counteract the errant effects of Src kinases. They developed strains of mice with high levels of Srcasm, which had normal skin, and other strains that over-expressed the Src-kinase called Fyn, which resulted in uncontrolled cell growth with thick, scaly, hairless plaque s on the skin. These plaques, or lesions, resembled precursors of cancer. Breeding experiments with the mice indicated that high Srcasm levels counteracted the effects of Fyn.

The findings reveal that levels of Fyn and Srcasm work in a kind of see-saw ?when Srcasm production is low, dangerous amounts of Fyn can build up in cells. But when Srcasm production is increased, Fyn levels go down. "The binding of Srcasm to Fyn regulates Fyn's persistence in the cell," says Seykora. "If Srcasm is low, Fyn persists longer and sends more growth-promoting signals."

Reversing Tumors
Eventually, Srcasm might play a role in targeted gene therapies for cancers that are triggered by activated Src kinases. Such a therapy would likely use an adenovirus to carry a gene that codes for Srcasm into skin cells to increase Srcasm production, as used in some other gene therapy treatments. Initially, clinicians may try this method on oral cavity and skin cancers.

Next, the Penn researchers will determine whether Srcasm can actually reverse tumor formation in skin. Seykora's team has already prepared an adenovirus and mice with the tumor-forming Src kinases expressed in their skin. Within six months, the group expects to know whether Srcasm can decrease squamous cell carcinoma formation in skin, mentions Seykora.
'"/>

Source:University of Pennsylvania School of Medicine


Related biology news :

1. Signaling protein builds bigger, better bones in mice
2. Computational Method Speeds Mapping of Cell Signaling Networks
3. Signaling for cartilage
4. New, automated tool successfully classifies and relates proteins in unprecedented way
5. New binding target for oncogenic viral protein
6. Controversial drug shown to act on brain protein to cut alcohol use
7. Timing is everything: First step in protein building revealed
8. UWs Rosetta software to unlock secrets of many human proteins
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Ancient olfaction protein is shared by many bugs, offering new pest control target
11. Automatic extraction of gene/protein biological functions from biomedical text

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... As Outsourcing of Cell Line Development Services Drives the ... by Expanding their Service Portfolio and Collaborating with Biopharmaceutical ... cell banking market addresses market sizing, emerging trends, and ... in the market. The base year considered is 2015 ... The cell banking market is expected to grow ...
(Date:1/24/2017)... ORANGE COUNTY, Calif. , Jan. 24, 2017 ... respiratory testing solutions, announced today that in ... providing advanced respiratory assessment to the Roche FIREFISH ... muscular atrophy (SMA) develop respiratory insufficiency due to ... alpha motor neurons in the spinal cord. This ...
(Date:1/24/2017)... Reha Technology USA Inc. has ... . The need for Robotic technology in the rehab space ... in the surgical space. Project Walk – Boston ... and adding technology to their continuum of care. They now have ... repetitions which has been shown to improve gait with patients. The ...
(Date:1/24/2017)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... nervous system (CNS) diseases, is pleased to announce that ... with the U.S. Food and Drug Administration (FDA), a ... LevoCap ER (REL-1015, levorphanol extended release, abuse deterrent capsules) ... filing is achievable.   "The FDA,s input ...
Breaking Biology Technology: